Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 1.00 |
| ▸ | RXRB | P28702 | 7/20 | 1.00 |
| ▸ | RXRG | P48443 | 7/20 | 1.00 |
| ▸ | RARB | P10826 | 6/20 | 0.72 |
| ▸ | RARG | P13631 | 5/20 | 0.72 |
| ▸ | RARA | P10276 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | DRD1 | P21728 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904473 | 0.95 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6905696 | 0.87 | RXRA (0.77) | RXRARXRBRXRGRARBRARG | |
| Bexarotene SCHEMBL5322954 | 0.84 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| Bexarotene SCHEMBL29412584 | 0.84 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| Bexarotene SCHEMBL9025 | 0.84 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| Bexarotene SCHEMBL4432606 | 0.83 | RXRA (0.97) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6906120 | 0.82 | RXRA (0.77) | RXRARXRBRXRGRARBRARG | |
| Bexarotene SCHEMBL28672173 | 0.82 | RXRA (0.94) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL10842818 | 0.81 | RARB (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL10844307 | 0.81 | RARB (0.74) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005017185-A2 | HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS | LIGAND PHARMCEUTICALS INCORPORATED (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2020150668-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2005017185-A2 | HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS | LIGAND PHARMCEUTICALS INCORPORATED (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2004-08-19 | — | — | US | disclosed |
| US-6646008-B1 | Administering peroxisome proliferator activated receptor(PPAR) and retinoid acid receptor agonists such as 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl) nicotinic acid, for prophylaxis of tumors | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-11-11 | — | — | US | disclosed |
| US-6586455-B1 | Administering retinoid and peroxisome proliferator-activated receptors to improve cell proliferation and differentiation of adipocytes; prophylaxis of cancer | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | PPARA, PPARG, PPARD | RXRA 6/4885RXRB 5/4885RXRG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.